Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.58 |
| ▸ | CCNC | P24863 | 1/20 | 0.51 |
| ▸ | CDK8 | P49336 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | LDHA | P00338 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12582221 | 0.85 | CCNC (0.49) | BRD4CCNCCDK8KDM4EALDH1A1 | |
| SCHEMBL16115664 | 0.84 | CCNC (0.73) | BRD4CCNCCDK8KDM4EALDH1A1 | |
| SCHEMBL25181069 | 0.83 | KDM4E (0.52) | BRD4CCNCCDK8KDM4EALDH1A1 | |
| SCHEMBL1254366 | 0.82 | NR4A2 (0.54) | BRD4CCNCCDK8KDM4EALDH1A1 | |
| SCHEMBL16691879 | 0.81 | CCNC (0.45) | BRD4CCNCCDK8MCL1CYP2C9 | |
| SCHEMBL16691871 | 0.80 | KDM1A (0.51) | BRD4CCNCCDK8KDM4EALDH1A1 | |
| SCHEMBL8461460 | 0.80 | CYP2C9 (0.55) | ALDH1A1GLACYP2C9KMT2AMEN1 | |
| SCHEMBL1126661 | 0.79 | P2RY12 (0.51) | BRD4KDM4EALDH1A1GAACYP2C9 | |
| SCHEMBL27660324 | 0.78 | LDHA (0.41) | BRD4KDM4EALDH1A1MCL1LDHA | |
| SCHEMBL17266950 | 0.77 | MAPT (0.45) | BRD4CCNCCDK8KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-11-13 | — | — | US | disclosed |
| EP-4431505-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2024-09-18 | — | — | EP | disclosed |
| CN-118234721-A | Isoindolinone derivative with glutarimide mother nucleus and application thereof | 韩国化学研究院 | 2024-06-21 | — | — | CN | disclosed |
| WO-2023085785-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | 한국화학연구원 | 2023-05-19 | — | — | WO | disclosed |
| US-9452168-B2 | Pyrrole antifungal agents | F2G LTD (GB) | 2016-09-27 | — | — | US | disclosed |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-08-27 | — | — | US | disclosed |
| US-8993574-B2 | Pyrrole antifungal agents | F2G LTD (GB) | 2015-03-31 | — | — | US | disclosed |
| EP-2283006-B1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-02-25 | — | — | EP | disclosed |
| EP-2626361-B1 | Pyrrole antifungal agents | F2G LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| CN-103833775-A | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS INC | 2014-06-04 | — | — | CN | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| CN-101801981-A | Sirtuin-modulating thiazolopyridine compounds | SIRTRIS PHARMACEUTICALS INC | 2010-08-11 | — | — | CN | disclosed |
| EP-2170905-A2 | SIRTUIN MODULATING THIAZOLOPYRIDINE COMPOUNDS | Sirtris Pharmaceuticals, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009130481-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2009-10-29 | — | — | WO | disclosed |
| US-20090105246-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105246-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105246-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2008156869-A2 | SIRTUIN MODULATING THIAZOLOPYRIDINE COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156869-A2 | SIRTUIN MODULATING THIAZOLOPYRIDINE COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105246-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | BRD4 156/4885CCNC 3260/4885CDK8 796/4885 |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | FOXM1, PYCR1, ARG1 | BRD4 3630/4885CCNC 2243/4885CDK8 3349/4885 |
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | CRBN, IDH1, IDH2 | BRD4 324/4885CCNC 2659/4885CDK8 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.